On Tuesday, Ocular Therapeutix Inc (NASDAQ: OCUL) was -5.14% drop from the session before settling in for the closing price of $8.75. A 52-week range for OCUL has been $5.34 – $11.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 72.05% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -17.19%. With a float of $133.72 million, this company’s outstanding shares have now reached $159.26 million.
In an organization with 274 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.66%, operating margin of -342.52%, and the pretax margin is -323.44%.
Ocular Therapeutix Inc (OCUL) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ocular Therapeutix Inc stocks. The insider ownership of Ocular Therapeutix Inc is 16.05%, while institutional ownership is 74.31%. The most recent insider transaction that took place on Jun 02 ’25, was worth 111,581. In this transaction Chief Medical Officer of this company sold 13,861 shares at a rate of $8.05, taking the stock ownership to the 206,805 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Officer proposed sale 13,861 for $8.05, making the entire transaction worth $111,524.
Ocular Therapeutix Inc (OCUL) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -17.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.61% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
You can see what Ocular Therapeutix Inc (OCUL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Let’s dig in a bit further. During the last 5-days, its volume was 4.06 million. That was better than the volume of 1.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 38.65%. Additionally, its Average True Range was 0.50.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 69.38%, which indicates a significant increase from 35.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.50% in the past 14 days, which was lower than the 79.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.74, while its 200-day Moving Average is $8.45. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $8.65. Second resistance stands at $9.01. The third major resistance level sits at $9.20. If the price goes on to break the first support level at $8.10, it is likely to go to the next support level at $7.91. The third support level lies at $7.55 if the price breaches the second support level.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are 159,300K outstanding shares of the company, which has a market capitalization of 1.32 billion. As of now, sales total 63,720 K while income totals -193,510 K. Its latest quarter income was 10,700 K while its last quarter net income were -64,050 K.
